By Nate Raymond
BOSTON (Reuters) – Sanofi SA (PA:) has agreed to pay $11.85 million to resolve U.S. allegations that it used a charity that helps cover Medicare patients’ out-of-pocket drug costs as a means to pay them kickbacks to use a high-priced multiple sclerosis drug.
The deal, announced by the U.S. Justice Department on Friday, was the latest to result from an industry-wide probe of drugmakers’ financial support of patient assistance charities that has resulted in more than $865 million in settlements.
The government said Sanofi provided payments to one such charity, The Assistance Fund, not with a charitable purpose in mind but instead to use it as a means to cover the co-pay obligations of Medicare patients using the MS drug Lemtrada.
TAF like other charities in the probe provide assistance to patients seeking to pay out-of-pocket costs for medications. Sanofi, whose drug costs nearly $100,000 per year per patient, made payments to the charity from 2015 to 2016, the department said.
“Sanofi used a supposed charity as a conduit to funnel money to patients taking Sanofi’s very expensive drug, all at the expense of the Medicare program,” U.S. Attorney Andrew Lelling in Boston said in a statement.
Sanofi did not admit wrongdoing as part of the settlement. The drugmaker in a statement defended the practice of providing financial support to such charitable organizations, saying it “believes these programs help patients lead healthier lives.”
Drug companies are prohibited from subsidizing co-payments for patients enrolled in the government’s Medicare healthcare program for those aged 65 and older. Companies may donate to non-profits providing co-pay assistance as long as they are independent.
But the government has alleged that various drugmakers have used charities like Orlando, Florida-based TAF as means to improperly pay the co-pay obligations of Medicare patients using their drugs, in violation of the Anti-Kickback Statute.
The investigation, led by the U.S. attorney’s office in Boston, came amid growing attention to soaring U.S. drug prices. Co-pays are partly meant to serve as a check on healthcare expenses by exposing patients to some of a medicine’s cost.
TAF did not immediately respond to a request for comment on Friday. It reached a separate $4 million settlement with the government in November resolving similar allegations involving three other pharmaceutical companies.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.